Financial Performance - In Q4 2025, the company reported revenue of $1.318 billion, a year-over-year increase of 6.20%, and a net profit of $63 million, a significant increase of 3250%, marking a return to profitability [1] - For the full year 2025, total revenue reached $5.421 billion, up 5.73% compared to the previous year, with earnings per share (EPS) of $3.36, significantly exceeding market expectations [1] Financial Condition - The debt-to-equity ratio improved from 135.7% to 32.09% over the past five years, well below the industry average of 194.31%, indicating enhanced debt repayment capacity [2] - In Q4, operating cash flow was $205 million, with free cash flow at $171 million; for the full year, operating cash flow totaled $440 million, supporting a dividend payout of $0.68 per share and a share buyback plan of $55 million in Q2 2025 [2] Operating Status - The gross margin for Q4 was 18.82%, while the gross margin for Q3 2025 had risen to 20.33%, benefiting from optimized product mix [3] - The company's price-to-earnings (P/E) ratio was 7.38 and the price-to-sales (P/S) ratio was 0.67, both lower than the industry averages of 18.03 and 2.86, respectively, indicating relative undervaluation [3] Institutional Views - Citigroup raised its target price from $52 to $62 on January 13, 2026, maintaining a "Hold" rating; Morgan Stanley upgraded to "Buy" with a target price of $60 on December 10, 2025 [4] Stock Performance - Following the earnings report, the stock price surged by 16.57% on February 11, closing at $69.08; as of February 13, the latest stock price was $69.23, reflecting a cumulative increase of 10.34% over the past five days [5] Recent Company Status - In Q3 2025, revenue declined by 6.05% year-over-year, and EPS fell by 16.57%, primarily due to global supply chain disruptions; increased competition in the industry necessitates attention to market share differences with giants like Caterpillar and Komatsu [6]

分组1 - Baxter International reported quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.53 per share, and down from $0.58 per share a year ago, representing an earnings surprise of -17.42% [1] - The company posted revenues of $2.97 billion for the quarter, surpassing the Zacks Consensus Estimate by 6.44%, compared to year-ago revenues of $2.75 billion [2] - Baxter shares have increased approximately 16.5% since the beginning of the year, outperforming the S&P 500's gain of 1.4% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.50 on revenues of $2.64 billion, and for the current fiscal year, it is $2.33 on revenues of $11.28 billion [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 33% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Viewpoint - Citigroup maintains a "Buy" rating for Burlington Stores (BURL.N) with a target price of $351, indicating optimism about the company's growth prospects in the discount retail sector [1][2]. Group 1: Institutional Perspective - The target price of $351 represents a premium over the closing price of $304.62 on the day of the report, reflecting a positive outlook from the institution regarding the company's future performance [1][2]. Group 2: Recent Stock Performance - Over the past 7 days (as of February 10, 2026), Burlington Stores' stock price exhibited a volatility range of 6.20%, with a cumulative increase of 1.43%. The latest closing price was $304.62, with a single-day decline of 4.35% on February 10, 2026, and a trading volume of approximately $296 million, resulting in a turnover rate of 1.54% [3]. - During the same period, the S&P 500 index rose by 0.86%, indicating that the company's stock performance outpaced the broader market [3].

分组1 - Mirion Technologies reported quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.16 per share, and down from $0.17 per share a year ago, representing an earnings surprise of -7.41% [1] - The company posted revenues of $277.4 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 1.57%, compared to year-ago revenues of $254.3 million [2] - Over the last four quarters, Mirion Technologies has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] 分组2 - The stock has added about 2.9% since the beginning of the year, outperforming the S&P 500's gain of 1.7% [3] - The current consensus EPS estimate for the coming quarter is $0.12 on $254.69 million in revenues, and $0.60 on $1.14 billion in revenues for the current fiscal year [7] - The Zacks Industry Rank indicates that the Technology Services sector is currently in the bottom 36% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

分组1 - Upstart Holdings, Inc. reported quarterly earnings of $0.46 per share, missing the Zacks Consensus Estimate of $0.47 per share, but showing an increase from $0.26 per share a year ago, resulting in an earnings surprise of -1.60% [1] - The company posted revenues of $296.09 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.64%, and up from $218.96 million year-over-year [2] - Upstart has surpassed consensus EPS estimates three times over the last four quarters, indicating a trend of positive performance in revenue estimates as well [2] 分组2 - The stock has underperformed the market, losing about 11.2% since the beginning of the year compared to the S&P 500's gain of 1.7% [3] - The current consensus EPS estimate for the coming quarter is $0.54 on revenues of $257.77 million, and for the current fiscal year, it is $2.65 on revenues of $1.24 billion [7] - The Financial - Miscellaneous Services industry, to which Upstart belongs, is currently in the top 27% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

Core Insights - Robinhood Markets Inc (NASDAQ:HOOD) is set to report its fourth-quarter results on February 12, indicating a significant moment for the company as earnings season continues [1] Performance Trends - Historically, HOOD has underperformed after earnings reports, with a decline in five of the last eight reports, including a notable 10.8% drop in November [2] - Over the past two years, the stock has averaged a price swing of 8.6%, while options traders are anticipating a larger swing of 16.5% for the upcoming report [2] Current Stock Activity - Robinhood's stock is currently on the short sale restricted (SSR) list, down 10.7% at $72.03, marking its worst day on record amid a Bitcoin selloff, and is experiencing its longest losing streak since August 2023 with an overall decline of 35.4% in 2026 [3] Short Interest and Analyst Ratings - Short interest has decreased by 17.7% over the past two reporting periods, representing 4.3% of the stock's available float, suggesting that it would take shorts less than two days to cover their positions [5] - Currently, 16 out of 22 analysts maintain a "buy" or better rating, indicating potential downgrades may be overdue [5] Options Trading Sentiment - Despite the negative price movement, call traders are showing increased interest, with a 10-day call/put volume ratio of 2.59, which is higher than 72% of readings from the past year [6] - Short-term options traders are exhibiting bullish sentiment, as indicated by a put/call open interest ratio of 0.64, which is in the 27th percentile of annual readings, suggesting that a reversal of this sentiment could lead to further challenges [7] - The stock's Volatility Scorecard (SVS) is at 76 out of 100, indicating that HOOD has consistently experienced higher volatility than what its options pricing suggests [7]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Eaton (ETN), and highlights the potential misalignment of interests between brokerage analysts and retail investors [1][5]. Group 1: Brokerage Recommendations for Eaton - Eaton has an average brokerage recommendation (ABR) of 1.67, indicating a consensus between Strong Buy and Buy, based on 24 brokerage firms [2]. - Out of the 24 recommendations, 15 are classified as Strong Buy (62.5%) and 2 as Buy (8.3%) [2]. Group 2: Limitations of Brokerage Recommendations - The article suggests that relying solely on brokerage recommendations may not be wise, as studies indicate limited success in guiding investors towards stocks with the best price increase potential [5]. - Analysts from brokerage firms tend to exhibit a strong positive bias in their ratings, with five "Strong Buy" recommendations for every "Strong Sell" [6][11]. Group 3: Zacks Rank vs. ABR - Zacks Rank is presented as a more reliable tool for stock performance prediction, categorizing stocks from Zacks Rank 1 (Strong Buy) to 5 (Strong Sell) based on earnings estimate revisions [8][12]. - The ABR is based solely on brokerage recommendations and may not be up-to-date, while Zacks Rank reflects timely earnings estimate revisions [13]. Group 4: Current Outlook for Eaton - The Zacks Consensus Estimate for Eaton has declined by 2.4% over the past month to $13.46, indicating growing pessimism among analysts regarding the company's earnings prospects [14]. - This decline in earnings estimates has resulted in a Zacks Rank 4 (Sell) for Eaton, suggesting caution despite the Buy-equivalent ABR [15].

分组1 - Steris reported quarterly earnings of $2.53 per share, matching the Zacks Consensus Estimate, and showing an increase from $2.32 per share a year ago, with an earnings surprise of -0.10% [1] - The company achieved revenues of $1.5 billion for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.08%, and up from $1.37 billion year-over-year [2] - Steris has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] 分组2 - The stock has gained approximately 3.2% since the beginning of the year, outperforming the S&P 500's gain of 1.1% [3] - The current consensus EPS estimate for the upcoming quarter is $2.88 on revenues of $1.6 billion, and for the current fiscal year, it is $10.23 on revenues of $5.93 billion [7] - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Ulta Beauty (ULTA), and emphasizes the importance of using these recommendations in conjunction with other analytical tools like the Zacks Rank for making informed investment decisions [1][5]. Group 1: Brokerage Recommendations - Ulta Beauty has an average brokerage recommendation (ABR) of 1.79, indicating a consensus between Strong Buy and Buy, based on 26 brokerage firms' recommendations [2]. - Out of the 26 recommendations, 16 are classified as Strong Buy, accounting for 61.5%, while one is classified as Buy, making up 3.9% of the total [2]. Group 2: Limitations of Brokerage Recommendations - The article highlights that brokerage recommendations may not be reliable indicators of stock performance due to the vested interests of brokerage firms, which often lead to a bias in favor of positive ratings [6][11]. - Research indicates that for every "Strong Sell" recommendation, there are five "Strong Buy" recommendations, suggesting a significant bias in the ratings provided by analysts [6]. Group 3: Zacks Rank as an Alternative - The Zacks Rank is presented as a more reliable tool for predicting near-term stock performance, based on earnings estimate revisions rather than brokerage recommendations [8][12]. - The Zacks Rank is distinct from the ABR, as it is a quantitative model that reflects timely changes in earnings estimates, while the ABR may not always be up-to-date [10][13]. Group 4: Ulta's Earnings Estimates - The Zacks Consensus Estimate for Ulta has increased by 0.2% over the past month to $25.57, indicating growing optimism among analysts regarding the company's earnings prospects [14]. - This increase in earnings estimates has contributed to Ulta receiving a Zacks Rank 1 (Strong Buy), suggesting a positive outlook for the stock [15].

Institutional Holdings - Several institutional investors have recently modified their holdings in PVH, with BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquiring a new position valued at $38,000 [1] - Hantz Financial Services Inc. increased its holdings by 1,284.4%, now owning 623 shares valued at $43,000 after acquiring an additional 578 shares [1] - Mirae Asset Global Investments Co. Ltd. grew its holdings by 45.6%, now owning 907 shares worth $62,000 after purchasing an additional 284 shares [1] - Blue Trust Inc. increased its stake by 41.2%, now owning 952 shares valued at $65,000 after acquiring an additional 278 shares [1] - Fifth Third Bancorp grew its stake by 28.9%, now owning 1,061 shares worth $73,000 after purchasing an additional 238 shares [1] - Institutional investors currently own 97.25% of PVH's stock [1] Stock Performance - PVH opened at $62.37, with a 1-year low of $59.28 and a 1-year high of $92.60 [2] - The company has a market cap of $2.86 billion, a P/E ratio of 9.35, and a PEG ratio of 2.21 [2] - PVH has a debt-to-equity ratio of 0.46, a current ratio of 1.47, and a quick ratio of 0.72 [2] - The 50-day simple moving average is $70.69, and the 200-day simple moving average is $76.61 [2] Earnings Report - PVH reported $2.83 earnings per share for the last quarter, exceeding analysts' estimates of $2.56 by $0.27 [3] - The firm had revenue of $2.29 billion, slightly above analyst estimates of $2.28 billion [3] - The company's quarterly revenue increased by 1.7% compared to the same quarter last year [3] - PVH's return on equity was 11.44%, and the net margin was 3.87% [3] - Guidance for Q4 2025 is set at 3.200-3.350 EPS, and FY 2025 guidance is 10.850-11.000 EPS [3] - Analysts forecast PVH will post 11.67 earnings per share for the current fiscal year [3] Analyst Ratings - Wells Fargo & Company reduced their target price on PVH from $88.00 to $85.00, maintaining an "equal weight" rating [4] - Needham & Company LLC reiterated a "buy" rating with a target price of $100.00 [4] - Telsey Advisory Group reaffirmed an "outperform" rating with a target price of $95.00 [4] - JPMorgan Chase & Co. raised their price target from $82.00 to $83.00, giving a "neutral" rating [4] - Eight analysts rated the stock as a Buy, while nine issued a Hold rating, with an average target price of $91.60 [4] Company Profile - PVH Corp is a leading global apparel company known for its portfolio of iconic brands, including Calvin Klein and Tommy Hilfiger [5] - The company designs, markets, and distributes clothing, accessories, and fragrances under both owned and licensed brands [5] - PVH's operations span the entire value chain from product design and development to manufacturing, marketing, and distribution [7]